See more : Impex Ferro Tech Limited (IMPEXFERRO.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Apollomics, Inc. (APLM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apollomics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Semiconductor Manufacturing International Corporation (688981.SS) Income Statement Analysis – Financial Results
- Investec Group (INL.JO) Income Statement Analysis – Financial Results
- PT Indospring Tbk (INDS.JK) Income Statement Analysis – Financial Results
- Beiersdorf Aktiengesellschaft (BDRFY) Income Statement Analysis – Financial Results
- Vodafone Group Public Limited Company (0LQQ.L) Income Statement Analysis – Financial Results
Apollomics, Inc. (APLM)
About Apollomics, Inc.
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 821.00K | 323.00K | 2.00K | 1.84M | 0.00 |
| Cost of Revenue | 694.00K | 775.00K | 681.00K | 609.00K | 369.00K |
| Gross Profit | 127.00K | -452.00K | -679.00K | 1.23M | -369.00K |
| Gross Profit Ratio | 15.47% | -139.94% | -33,950.00% | 66.87% | 0.00% |
| Research & Development | 34.19M | 35.46M | 35.57M | 31.44M | 18.44M |
| General & Administrative | 20.64M | 9.95M | 15.29M | 11.04M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 20.64M | 9.95M | 15.29M | 11.04M | 5.94M |
| Other Expenses | 0.00 | -196.25M | -41.95M | -29.88M | 0.00 |
| Operating Expenses | 54.14M | 44.39M | 50.27M | 40.75M | 24.38M |
| Cost & Expenses | 54.83M | 44.39M | 50.27M | 40.75M | 24.75M |
| Interest Income | 0.00 | 431.00K | 467.00K | 330.00K | 702.00K |
| Interest Expense | 150.00K | 93.00K | 83.00K | 72.00K | 46.00K |
| Depreciation & Amortization | 694.00K | 775.00K | 681.00K | 609.00K | 369.00K |
| EBITDA | -171.75M | -239.94M | -94.03M | -74.22M | -45.34M |
| EBITDA Ratio | -20,919.24% | -74,128.79% | -4,553,500.00% | -3,997.61% | 0.00% |
| Operating Income | -54.83M | -240.21M | -91.75M | -74.09M | -24.75M |
| Operating Income Ratio | -6,678.93% | -74,368.73% | -4,587,550.00% | -4,030.74% | 0.00% |
| Total Other Income/Expenses | -117.76M | -196.75M | -44.53M | -34.26M | -21.00M |
| Income Before Tax | -172.59M | -240.81M | -94.80M | -74.91M | -45.75M |
| Income Before Tax Ratio | -21,022.05% | -74,554.18% | -4,739,800.00% | -4,075.35% | 0.00% |
| Income Tax Expense | 10.00K | 1.00K | 1.00K | -85.00K | 153.00K |
| Net Income | -172.60M | -240.81M | -94.80M | -74.82M | -45.91M |
| Net Income Ratio | -21,023.26% | -74,554.49% | -4,739,850.00% | -4,070.73% | 0.00% |
| EPS | -2.32 | -2.77 | -1.09 | -0.86 | -0.53 |
| EPS Diluted | -2.32 | -2.77 | -1.09 | -0.86 | -0.53 |
| Weighted Avg Shares Out | 74.40M | 86.80M | 86.80M | 86.80M | 86.80M |
| Weighted Avg Shares Out (Dil) | 74.40M | 86.80M | 86.80M | 86.80M | 86.80M |
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline
The 7 Most Promising Penny Stocks to Buy in June
Why Shares of Apollomics Are Up Friday
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)
Source: https://incomestatements.info
Category: Stock Reports